2QK Stock Overview A biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Scholar Rock Holding Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Scholar Rock Holding Historical stock prices Current Share Price US$42.80 52 Week High US$45.00 52 Week Low US$6.15 Beta 0.54 1 Month Change 18.89% 3 Month Change 478.38% 1 Year Change 147.40% 3 Year Change 92.79% 5 Year Change 292.66% Change since IPO 355.32%
Recent News & Updates Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million. Oct 10
Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million. Oct 09
Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million. Oct 08
Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy Oct 07
Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer Sep 04
New major risk - Financial position Aug 09 See more updates Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million. Oct 10
Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million. Oct 09
Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million. Oct 08
Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy Oct 07
Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer Sep 04
New major risk - Financial position Aug 09
Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal Jun 24
Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting May 29
Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024 May 01
New major risk - Shareholder dilution Apr 19
New major risk - Financial position Mar 20
President recently sold €170k worth of stock Feb 22
Scholar Rock Announces Management Appointments Feb 15
Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management Feb 06
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity Jan 23
Senior VP & Head of Research recently sold €268k worth of stock Dec 17
New major risk - Revenue and earnings growth Nov 08
Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability Nov 04
Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting Oct 20 Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million. Oct 13
Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.
Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial Sep 20
Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab Jul 01
Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023 May 04
Full year 2022 earnings released: US$2.26 loss per share (vs US$3.59 loss in FY 2021) Mar 08
Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer Feb 07
Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021) Nov 16
Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy Nov 11
Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer Nov 10
Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA Oct 23 Scholar Rock Announces Chief Executive Officer Changes
Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021) Aug 10
Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors Jul 27 Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index
Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment Jun 18 Scholar Rock Holding Corporation Provides Pipeline Updates
First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.76 loss in 1Q 2021) May 17
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 08
Scholar Rock Holding Corporation Provides Corporate Update and Highlights Priorities for 2022 Jan 12
Scholar Rock Holding Corporation Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA) Dec 01
Third quarter 2021 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2020) Nov 10
Scholar Rock Holding Corporation Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress Sep 24
Second quarter 2021 earnings released: US$0.84 loss per share (vs US$0.65 loss in 2Q 2020) Aug 11
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress Jun 19
Forecast to breakeven in 2025 Jun 16
Scholar Rock Announces Oral Presentation of TOPAZ Phase 2 Trail Results at the 2021 Virtual SMA Research & Clinical Care Meeting Jun 12
Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting Jun 08
Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy May 25
Scholar Rock Holding Corporation to Present Trials in Progress Poster for Srk-181 Dragon Phase 1 Clinical Trial At the American Society of Clinical Oncology Annual Meeting May 21
Forecast to breakeven in 2025 May 18
First quarter 2021 earnings released: US$0.76 loss per share (vs US$0.58 loss in 1Q 2020) May 16
Scholar Rock Announces Publication of Phase 1 Clinical Trial Data Evaluating Apitegromab in Healthy Volunteers in the Journal Advances in Therapy May 12
Scholar Rock Announces the Addition of Joshua Reed to Its Board of Directors Mar 20
Full year 2020 earnings released: US$2.81 loss per share (vs US$1.85 loss in FY 2019) Mar 11
Revenue misses expectations Mar 11
New 90-day high: €50.00 Feb 06
Scholar Rock Announces Executive Promotions Feb 05
New 90-day high: €47.40 Jan 15
New 90-day high: €43.80 Dec 02
Third quarter 2020 earnings released: US$0.79 loss per share Nov 11
Revenue misses expectations Nov 11
New 90-day high: €31.80 Oct 29
Earnings released Aug 07
Scholar Rock Holding Corporation to Report Q2, 2020 Results on Aug 07, 2020 Aug 06
Scholar Rock Holding Corporation Announces Executive Changes, Effective August 1, 2020 Jul 17 Shareholder Returns 2QK DE Biotechs DE Market 7D 7.0% 1.2% -0.3% 1Y 147.4% -14.3% 7.0%
See full shareholder returns
Return vs Market: 2QK exceeded the German Market which returned 7% over the past year.
Price Volatility Is 2QK's price volatile compared to industry and market? 2QK volatility 2QK Average Weekly Movement 102.4% Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2QK's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2QK's weekly volatility has increased from 51% to 102% over the past year.
About the Company Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia.
Show more Scholar Rock Holding Corporation Fundamentals Summary How do Scholar Rock Holding's earnings and revenue compare to its market cap? 2QK fundamental statistics Market cap €4.10b Earnings (TTM ) -€217.11m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2QK income statement (TTM ) Revenue US$0 Cost of Revenue US$169.15m Gross Profit -US$169.15m Other Expenses US$56.82m Earnings -US$225.97m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 07:24 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Scholar Rock Holding Corporation is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Madhu Kumar Baird Etzer Darout BMO Capital Markets Equity Research Guyn Kim BMO Capital Markets Equity Research
Show 13 more analysts 
